Eating and swallowing issues, along with meal planning and prep, can become challenging due to MS symptoms such as fatigue ...
Multiple sclerosis (MS) is a disease that affects the brain and spinal cord. It happens when the body’s immune system ...
We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...
Brii Biosciences Inc. has identified substituted 2-(3,5-dichloro-4-(4-hydroxy-benzyl)phenoxy)acetamide derivatives that are prodrugs of thyroid hormone receptor β (TH-β) agonists and reported to be ...
Experts in Australia and New Zealand have published the first consensus guidelines for the care of adults with MS in those ...
The company is expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis, as ...
While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.
The first clinical consensus statement for managing multiple sclerosis (MS) in Australia and New Zealand has been released, ...
hsr.it Objective To investigate monoaminergic network abnormalities in patients with multiple sclerosis (MS) according to their ... these bothersome symptoms and putative targets for their treatment.
Stem cells are an intriguing option because they could, in theory, build you a new immune system—one ... safety and effectiveness of stem cell treatment for MS. Dargahi N, Katsara M, Tselios T, et al.
Damage to myelin, the protective sheath surrounding nerve fibers, impairs the brain's ability to transmit signals efficiently. This condition, known as demyelination, disrupts motor function, sensory ...